Clinical trials: Coccidioidomycosis
- Condition Coccidioidomycosis
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Malaria
Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children
GSK Biologicals is developing a number of candidate malaria vaccines for the routine immunization of infants and children living in malaria-endemic areas.
- Trial name
- NCT00307021
- Testing
- GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049
- Where
- Gabon
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Toxoplasmosis
Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects
Pyrimethamine in combination with a sulphonamide is known to be effective in the treatment of toxoplasmosis. However, Pyrimethamine has not been approved by the Japanese regulatory body (Pharmaceutical and Medical Devices Agency…
- Trial name
- NCT03258762
- Testing
- Pyrimethamine, Calcium folinate
- Where
- Australia
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria, Malaria Vaccines
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
GSK Biologicals in partnership with the Malaria Vaccine Initiative at PATH is developing a candidate malaria vaccine GSK 257049 for the routine immunization of infants and children living in malaria endemic areas.
- Trial name
- NCT00289185
- Testing
- RTS,S/AS02D, Engerix-B®, TETRActHib™
- Where
- Tanzania
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cryptosporidiosis
Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults
This study has the purpose to demonstrate prospect of benefit of EDI048 on clinical signs and symptoms of cryptosporidiosis to facilitate trial in target population, pediatric patients.
- Trial name
- CRYPTONITE (NCT07249463)
- Testing
- Cryptosporidium parvum oocysts (ABO809), EDI048
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Rift Valley Fever
Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011
Phase 1 randomized, double-blind, placebo-controlled trial to evaluate safety, tolerability, pharmacokinetics (PK) and immunogenicity of IDB-011 following intramuscular (IM )administration of single ascending doses to healthy…
- Trial name
- NCT06925919
- Testing
- IDB-011 dose level 1, IDB-011 dose level 2, IDB-011 dose level 3
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- IDBiologics, Inc.
Coccidioidomycosis
A Multi-center Study of Spherule-Derived Coccidioidin
Adult volunteers were skin tested with 1.27 ug spherule-derived coccidioidin. The skin test antigen was evaluated in three different populations of adult volunteers to determine the safety and efficacy of the product in the…
- Trial name
- NCT00690092
- Testing
- Spherule-derived coccidioidin
- Where
- 4 sites in United States
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Nielsen BioSciences, Inc.
Cryptosporidium Infection, Cryptosporidiosis
Study of Efficacy and Safety of ABO809 in Healthy Participants
The purpose of this Phase I controlled human infection model (CHIM) study was to determine if oral administration of a good manufacturing practice (GMP) supply of Cryptosporidium parvum oocysts (ABO809) to healthy volunteers…
- Trial name
- NCT05036668
- Testing
- Cryptosporidium parvum oocysts (ABO809)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals